top of page



Logga C4C.png

Cell4Cure becomes member of the Association ATMP Sweden

Solna, Sweden, 8 January 2024, Cell4Cure AB - A Swedish private ATMP company working with antigen-specific dendritic cell mediated tolerance, aiming for curing disease where the immune system has become the enemy - today announced that they have joined the non profit organization ATMP Sweden.

Cell4Cure joins the association ATMP Sweden to strengthen its scientific and commercial network within the field of Advanced Therapy Medicinal Products (ATMP), a field that covers cell, gene and tissue-based therapies.

The Association ATMP Sweden is a non for profit association founded during 2023 with the aim to consolidate and further develop networking, communication and ATMP knowledge management in Sweden. The initiative of the network and communication platform started as a part of Swelife and CAMP initiatives, partly financed by VINNOVA, a governmental body promoting innovation and growth in Sweden.

Christina Herder, co-founder and board member: “To us in Cell4Cure it is important to actively take part in this fast-growing field and contribute to this important community platform for Swedish ATMP”.


For more information, please contact;

Christina Herder, CEO

Telephone: +46 703747156



About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit

bottom of page